SYRS, US87184Q2066

Syros approves wind-down: what it means for Syros Pharmaceuticals stock

Published on 10/06/2026 at 05:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syros approved a wind-down on February 28, 2025. Syros Pharmaceuticals stock was USD 0.0004 on September 11, 2026, below USD 0.0200.

SYRS, US87184Q2066, Illustration mit AI erstellt.

Syros Pharmaceuticals (ISIN US87184Q2066) had its board approve a voluntary Nasdaq delisting and wind-down on February 28, 2025, according to EdgeChat. Syros Pharmaceuticals stock later appeared in OTC market data at USD 0.0004 on September 11, 2026, versus a 52-week high of USD 0.0200.

What the wind-down means

The February 28, 2025 decision followed the failure of the SELECT-MDS-1 Phase 3 trial of tamibarotene with azacitidine to meet its primary endpoint, according to EdgeChat. The company agreed to operate under a budget approved by Oxford Finance and planned a Form 15 filing around March 20, 2025.

That sequence changed the investment case from a clinical-stage development story to a corporate wind-down. Syros had previously centered its pipeline on tamibarotene for genetically defined hematologic cancers, while SY-2101 and SY-5609 represented additional clinical programs.

From financing to delisting

The company closed its merger with Tyme Technologies on September 16, 2022, alongside a USD 130.00 million private investment in public equity, according to EdgeChat. The transaction added approximately USD 60.00 million in net cash at closing and left Syros trading on Nasdaq before the later delisting process.

Syros was incorporated on November 9, 2011, and entered Nasdaq trading in 2016. The company's investor-relations page describes its mission as developing new standards of care for frontline treatment of hematologic malignancies, linking the corporate history to the therapeutic focus.

OTC quote remains far below high

The dated OTC quote of USD 0.0004 on September 11, 2026 stood USD 0.0196 below the USD 0.0200 52-week high and matched the quoted prior close. The comparison shows how sharply the market value contracted from the historical public-company phase, while the wind-down places corporate actions ahead of a conventional earnings narrative.